Can SELLAS Stock Gain From Resistant Pancreatic Cancer Data
- SELLAS Life Sciences Group reported preclinical data on SLS009 in MYC amplified, RAS inhibitor resistant pancreatic ductal adenocarcinoma organoid models, showing meaningful cancer cell death alone and in combinations with daraxonrasib and BET inhibitor ZEN3694 at an AACR pancreatic cancer conference held in late September 2026.
- The new organoid findings highlight a potential route for SELLAS Life Sciences Group to address treatment resistance in high unmet need pancreatic cancer settings through a CDK9 focused approach that may support broader pipeline positioning across MYC driven, RAS inhibitor resistant tumors.
- This raises the question of how SELLAS Life Sciences Group's investment narrative could shift as SLS009 targets resistant pancreatic cancer biology.
What Is SELLAS Life Sciences Group's Investment Narrative?
Owning SELLAS Life Sciences Group is essentially a bet that a late stage oncology platform can turn science into durable cash flow before dilution and funding costs bite too hard. The preclinical SLS009 pancreatic data adds an extra angle to that story, hinting at breadth beyond GPS in leukemia. For the near term though, the business reality still leans on clear execution around GPS Phase 3, careful spend in the absence of revenue, and access to capital in a sector where trials are expensive and timelines can stretch.
The fresh organoid results around MYC driven, RAS inhibitor resistant PDAC may influence how investors think about the pipeline’s depth but they do not change the fact that SELLAS Life Sciences Group currently reports no revenue and a loss of US$32.5m. With the stock down 24.4% over 90 days but still showing a very large 1 year total return and trading on a rich P/B multiple versus peers, expectations remain high while volatility and dilution risk stay front and center.
Yet there is a less comfortable piece of the SELLAS Life Sciences Group story that often only becomes obvious when you look at ...
There's only one way to know the right time to buy, sell or hold SELLAS Life Sciences Group. Head to Simply Wall St's company report for the latest analysis of SELLAS Life Sciences Group's Fair Value.
Decide For Yourself
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your SELLAS Life Sciences Group research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- See our latest analysis for SELLAS Life Sciences Group. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate SELLAS Life Sciences Group's overall financial health at a glance.
Looking For More Investment Ideas Beyond SELLAS Life Sciences Group?
If SELLAS Life Sciences Group sits at the higher risk end of your watchlist, it can help to balance that exposure with other types of stocks that suit your goals and time horizon.
- For investors who want potential value combined with quality metrics, consider screening for companies through the 28 high quality undervalued stocks that may align better with your margin of safety preferences.
- If your priority is resilience and balance sheet strength, focus on businesses filtered by the list of solid balance sheet and fundamentals (25 results) to compare financial foundations side by side.
- Those who lose sleep over volatility can narrow the field using the 31 resilient stocks with low risk scores to identify stocks with lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com